CVS icon

CVS Health

71.21 USD
-0.09
0.13%
At close Aug 25, 4:00 PM EDT
Pre-market
71.37
+0.16
0.22%
1 day
-0.13%
5 days
1.79%
1 month
17.31%
3 months
16.09%
6 months
11.86%
Year to date
61.04%
1 year
21.31%
5 years
12.19%
10 years
-28.79%
 

About: CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health adds primary care services to the mix, which could have significant synergies with all existing business lines.

Employees: 300,000

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more call options, than puts

Call options by funds: $1.66B | Put options by funds: $1.33B

18% more first-time investments, than exits

New positions opened: 179 | Existing positions closed: 152

1.81% more ownership

Funds ownership: 84.38% [Q1] → 86.19% (+1.81%) [Q2]

4% more capital invested

Capital invested by funds: $72.1B [Q1] → $75.2B (+$3.1B) [Q2]

1% less funds holding

Funds holding: 1,728 [Q1] → 1,718 (-10) [Q2]

14% less funds holding in top 10

Funds holding in top 10: 37 [Q1] → 32 (-5) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 621 | Existing positions reduced: 718

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$79
11%
upside
Avg. target
$81
13%
upside
High target
$82
15%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
UBS
Kevin Caliendo
11%upside
$79
Buy
Upgraded
18 Aug 2025
Baird
Michael Ha
15%upside
$82
Outperform
Upgraded
14 Aug 2025
Morgan Stanley
Erin Wright
15%upside
$82
Overweight
Maintained
1 Aug 2025
Barclays
Andrew Mok
12%upside
$80
Overweight
Maintained
1 Aug 2025
Jefferies
Brian Tanquilut
12%upside
$80
Buy
Maintained
30 Jun 2025

Financial journalist opinion

Based on 61 articles about CVS published over the past 30 days

Positive
CNBC Television
11 hours ago
CVS is up because it faced the pain that's now hitting the rest of managed care, says Jim Cramer
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.
CVS is up because it faced the pain that's now hitting the rest of managed care, says Jim Cramer
Positive
CNBC Television
11 hours ago
Jim Cramer talks what is driving CVS higher this year
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.
Jim Cramer talks what is driving CVS higher this year
Positive
Schwab Network
3 days ago
The Big 3: LLY, BA, CVS
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Boeing (BA) to soar on its financial recovery and aircraft backlog, and CVS Health (CVS) to capture more market share in the pharma space.
The Big 3: LLY, BA, CVS
Neutral
Zacks Investment Research
3 days ago
CVS Gains in Pharmacy & Consumer Wellness Despite Reimbursement Woes
CVS Health's Pharmacy & Consumer Wellness unit posts double-digit revenue gains despite ongoing reimbursement headwinds.
CVS Gains in Pharmacy & Consumer Wellness Despite Reimbursement Woes
Positive
Zacks Investment Research
4 days ago
4 Value Stocks Every Investor Should Hold in Volatile Times
StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.
4 Value Stocks Every Investor Should Hold in Volatile Times
Positive
Zacks Investment Research
4 days ago
Value Investing: 5 Undervalued Stocks Worth Adding to Your Portfolio
StoneCo, CVS Health, KT, KB Financial and USANA Health stand out as undervalued picks with low P/B ratios and solid growth prospects.
Value Investing: 5 Undervalued Stocks Worth Adding to Your Portfolio
Negative
Benzinga
4 days ago
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
Neutral
Investors Business Daily
4 days ago
CVS Health Stock Runs Hot Once Again, Hitting A New Buy Point
CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.
CVS Health Stock Runs Hot Once Again, Hitting A New Buy Point
Negative
Reuters
5 days ago
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness.
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
Positive
Zacks Investment Research
5 days ago
Should You Invest in CVS Health (CVS) Based on Bullish Wall Street Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Should You Invest in CVS Health (CVS) Based on Bullish Wall Street Views?
Charts implemented using Lightweight Charts™